Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

One of them is CRISPR Therapeutics ( CRSP -0.90%). It has an approved gene-editing therapy, but investors haven't been buying ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

CRISPR Therapeutics CRSP reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.27 per share. In the year-ago period, the company had ...